Lifeline Scientific, Inc Exercise of options, Admission of Shares and TVR (2668K)
26 7월 2013 - 9:25PM
UK Regulatory
TIDMLSI
RNS Number : 2668K
Lifeline Scientific, Inc
26 July 2013
Lifeline Scientific, Inc.
("Lifeline" or "the Company")
Exercise of options, Admission of Shares and TVR
Lifeline Scientific, the medical technology company focused on
the worldwide commercialization of its LifePort Kidney transporter,
a product designed to address the global challenge of human donor
organ shortages, announces that on 23 July 2013, an employee of the
Company exercised 30,000 options on a cashless basis, resulting in
21,761 common shares in the Company at an exercise price of 39
pence per common share. Application has been made for admission of
the common shares to trading on the AIM market and Admission is
expected to occur on 31 July 2013.
Total Voting Rights
Following this exercise of options, Lifeline has 19,446,720
common shares in issue and each share has the right to one vote.
Therefore for the purposes of the FSA Disclosure and Transparency
Rules the total number of voting rights in the Company is
19,446,720.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine whether they are
required to notify the Company of their interests in, or change to
their interests in, Lifeline Scientific, Inc. under the FSA's
Disclosure and Transparency Rules.
Following today's application, 6,717,805 common shares remain
subject to Regulation S restrictions and are held in certificated
form only. These common shares subject to Regulation S restrictions
are traded under ISIN number USU529641008.
The remaining 12,728,915 common shares have had the Regulation S
restrictions lifted and are held in uncertificated form trading
under ISIN number US53223V1017.
For further information:
Lifeline Scientific, Inc. Tel: +1 847-294-0300
David Kravitz, CEO
Panmure Gordon (UK) Limited Tel: +44 20 7886 2500
Freddy Crossley (Corporate Finance)
Adam Pollock / Victoria Boxall (Corporate
Broking)
Walbrook Tel: +44 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus
Lianne Cawthorne
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to provide improved kidney preservation, evaluation and
transport prior to transplantation. Today, it is widely recognised
as the world's leading machine preservation device for kidneys.
Employed by surgeons in over 135 leading transplant programmes in
23 countries worldwide, LifePorts have successfully preserved over
38,000 kidneys intended for clinical transplant. The product
provides a sealed, sterile, protected environment where a solution
is gently pumped through the kidney at cold temperatures to
minimise damage while the organ is outside the body. LifePort is
lightweight and portable, allowing organs to be perfused from the
time of recovery until transplant. It is designed to travel
unaccompanied by land or air, safely transporting the kidneys
across town or between countries. While the kidney is being
perfused, LifePort records data on temperature, flow rate, vascular
resistance and pressure every 10 seconds providing surgeons with
additional data prior to transplant. LifePort is the only system
with clinical outcomes data produced from an independent,
prospective, randomised, statistically powered, multi-centre
clinical trial. Study results have been widely published in
scientific journals, including the New England Journal of Medicine.
Data indicates that patients receiving LifePort preserved kidneys
experienced significant reduction in the incidence and duration of
delayed graft function and increased graft survival at 1-year and
3-years post transplant. LifePort has also been recognised for its
design and engineering. It has received prominent awards for design
excellence from the medical device industry, has been selected for
exhibition at the Smithsonian Cooper-Hewitt, National Design Museum
and is part of the permanent Collection of The Museum of Modern Art
(MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product is the FDA cleared, CE marked and
clinically validated LifePort Kidney Transporter. Devices for
preservation of the liver, pancreas, heart, and lung are in late
stage pre-clinical development.
see www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMGZNZVFGFZM
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024